News in brief

Intralytix: Investment allows us to expand phage production

Intralytix: Investment allows us to enhance R&D programs, add high throughput robotic tech and expand phage production capabilities. Picture: ©iStock/arinarici

Intralytix has received $17.5m in equity funding from Lesaffre to create a series of novel bacteriophage-based products.

The investment marks the start of a collaboration between the companies to develop and commercialize such items.

Intralytix product targeting Shigella recently received GRAS (Generally Recognized As Safe) recognition from the US Food and Drug Administration (FDA).

The company has three FDA/USDA approved products: ListShield, to reduce or eliminate Listeria monocytogenes in food; EcoShield, for E. coli O157:H7 in red meat intended for grinding and SalmoFresh for Salmonella in poultry, fish, shellfish and fresh and processed fruits and vegetables.

Alexander Sulakvelidze, EVP and chief scientific officer of Intralytix, said: “This investment solidifies Intralytix's position as the leader in the field of bacteriophage research and commercialization, and allows us to strengthen the company infrastructure by enhancing our already superb R&D programs, adding high throughput robotic technologies, and expanding our state-of-the-art phage production capabilities."

John Woloszyn, Intralytix's CEO, said: "Phage-based products, when properly formulated and manufactured, provide a safe, effective and all-natural way to help maintain healthy microbiota.

“We believe that our collaboration with Lesaffre will significantly enhance and expedite product development and will ultimately benefit hundreds of thousands of people worldwide."

Lesaffre designs, manufactures and markets products for baking, food taste, health care and biotechnology. It employs 9,500 people in more than 70 subsidiaries, in about 40 countries.

The investment is in line with the French family group’s expansion strategy in nutrition and health.

In 2015, Lesaffre invested in Gnosis, an Italian company specialized in ingredients for the pharmaceutical, nutraceutical, cosmetic and veterinary industries.

Antoine Baule, Lesaffre's CEO, said it is looking forward to developing phage-based products and technologies.

"We believe that bacteriophage technology, mastered by Intralytix, offers an exciting platform for developing various antimicrobial products that will help reduce antibiotic resistance.”  

Related News

Production facility where Intralytix produces its phage preparations for food safety

Intralytix phage-based Shigella tech backed by FDA

Intralytix gets backing for phage-based product to control salmonella

Intralytix gains approval for phage-based salmonella control

EPA approved antimicrobial could control listeria in food plants

US army awards funding for antimicrobial agent


Phage tech draws a blank with many consumers - Micreos

Sample6 DETECT and Sample6 CONTROL are the firm's two food safety platforms

Sample6 awarded patent for tech behind pathogen detection platform

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.